Capricor Therap CAPR

$8.95 +0.01 (0.11%)

Valuation

Market cap
519,763,000
Revenue TTM
$0
Net income TTM
$-105,040,000
PE ratio
0.00
Forward PE
—
Profit margin
0.00%
Debt to equity
0.00

Trading

Volume
2,636,600
Avg volume
8,223,876
Day's range
$8.77 – $9.24
Shares out
58,139,000
Stochastic %K
31%
Beta
0.61
Analysts
Sell
Price target
$23.67

Price

Company profile

Capricor Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of transformative cell and exosome-based therapeutics for treating duchenne muscular dystrophy (DMD) and other diseases with unmet medical needs in the United States. Its lead product candidate is the Deramiocel, an allogeneic cardiosphere-derived cells, which is in phase 3 clinical trial for the treatment of DMD. The comp...

Show more

Capricor Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of transformative cell and exosome-based therapeutics for treating duchenne muscular dystrophy (DMD) and other diseases with unmet medical needs in the United States. Its lead product candidate is the Deramiocel, an allogeneic cardiosphere-derived cells, which is in phase 3 clinical trial for the treatment of DMD. The company also develops Exosome protein-based vaccine, which is in preclinical trial to treat SARS-CoV-2; StealthX Exosome Platform, and exosome platform program consists of engineered exosomes for vaccine and therapeutic development and is in preclinical trial. In addition, it engages in developing StealthX, an engineered exosome-based vaccine candidate, under phase 1 clinical study for a range of therapeutic applications, including targeted RNA, protein, and small molecule therapeutics to treat or prevent a variety of diseases; It has license agreement with Johns Hopkins University, University of Rome License, and Cedars-Sinai Medical Center to develop and commercialize licensed products and licensed services under the licensed patent rights in all fields and a nonexclusive right to the know-how; Cell Line License Agreement with Life Technologies for the development of exosomes platform. The company was founded in 2005 and is headquartered in San Diego, California.

Industry
Biotechnology
Sector
Healthcare
Phone
858 727 1755
Website
https://www.capricor.com
Address
10865 Road to the Cure, Suite 150, San Diego, United States

Latest news

Stocktwits

PeterRaslow Oct 3, 11:04 PM
$SLS so $CAPR did have an EAP and guess what ? they did share the results what the F are u hiding Sterg ? 4.5 years of EAP data and you could not find one private placement ? you had to give Anson all the free 40 million warrants ? yah makes no sense
0 replies
Dude2U Oct 3, 10:26 PM
$CAPR Nice day all in all.....
1 replies
JohnFromLongRobust Oct 3, 9:37 PM
$CAPR Trying to research the estimated target market. It seems if approved, co can make $100-150 million in the first year before expansion.
2 replies
quickaspeter Oct 3, 9:24 PM
$CAPR Good insight and thanks for sharing! The big one is coming…💥🚀💰💰💰
0 replies
Andromedian Oct 3, 8:50 PM
$CAPR Deramiocel will be approved by the FDA on or before the November 22 deadline. The approval will be for the skeletal muscle indication in DMD, that will be good enough to help the patients waiting for it! It is clear from the data that the drug works for patients with DMD cardiomyopathy too. Will the label will include cardiomyopathy as well? I sure hope so but I don’t know if that’s possible since the present BLA does not include cardiomyopathy as far as I know. Maybe somebody is more knowledgeable than me can comment on this point. See the attached post from WB - https://stocktwits.com/WBinthehouse/message/665702944
0 replies
GreylockSec Oct 3, 8:49 PM
$CAPR ...some interesting stats about 'If' the FDA might approve a 'major Amendment' much earlier than its PDUFA date, per Uncle Gemini-AI : ..."...The Regulatory Realities of Major Amendments The FDA Utilizes the Extra Time: Historical tracking shows the FDA meets its adjusted PDUFA goal dates at a rate exceeding 90%. However, the vast majority of these decisions—whether approvals or Complete Response Letters (CRLs)—are announced in the final 1 to 2 days leading up to the final PDUFA deadline. "Long Before" is a Rarity: The FDA rarely leaves months on the table after extending a clock. An approval occurring weeks or months before an extended PDUFA date typically only happens under narrow conditions, such as an unprecedented public health crisis. The Criteria for Extension: ...If the data were simple enough to review ahead of schedule, it likely wouldn't have been classified as a major amendment in the first place..."...so it appears we're waiting until Nov 😎
1 replies
Mauismart Oct 3, 8:32 PM
$CAPR an unsigned obsolete draft analysis plan was being used and the ceo was supposed to sot back and do nothing when lives are at stake. Use the right anaysis plan and make the right decision and approve this now. People are losing faith in these agencies.
0 replies
dnfrs Oct 3, 8:24 PM
$CAPR All the Deramiocel studies have confirmed what the Lancet article stated . Deramiocel benefits both skeletal and cardiac muscle. A label which includes both would be nice...but only one will get the drug to the boys who need it! What is exciting is that Capricor already has several StealthX exosome preclinical studies showing that other helpful drugs can be delivered more safely, in larger dosages and with greater specificity to muscles, lungs , brain and other vital organs. This applies to DMD, but also to other rare diseases and difficult to treat cancers . Once Deramiocel is approved ....all of these other programs will advance. Great days ahead!
0 replies